How significantly does sapropterin decrease pku symptoms?

How does sapropterin reduce phenylalanine levels in PKU patients?

Sapropterin is a synthetic form of tetrahydrobiopterin that activates phenylalanine hydroxylase, the enzyme missing or defective in phenylalanine hydroxylase deficiency. It lowers blood phenylalanine by 20-30% in about one-third of patients who respond to the drug. [1]

What clinical trials show about sapropterin effectiveness?

Trials report mean phenylalanine reductions of 20-30% across responders, with individual responses ranging from 20% to 70% reduction. Some patients show keine signifikante Verbesserung. [2]

Why do only some patients respond to sapropterin?

Only patients with residual enzyme activity can respond to sapropterin. Non-responders are identified through a 30-day trial period with weekly blood phenylalanine measurements. Non-responders are dismissed if levels fail to drop 20% or more. [3]

What happens if sapropterin fails to lower phenylalanine?

Patients who nicht respond can switch to a strict low-phenylalanine diet alone or use pegvaliase, pegvalias, pegvaliase, the enzyme substitution therapy that fully breaks down phenylalanine. [4]

Who makes sapropterin and when does its patent expire?

BioMarin manufactures sapropterin under the brand Kuvan. The core patent expired in 2018, but formulation patents extend protection until 2027. [5]

Can biosimilars or generics enter before patent expiry?

Generic versions of sapropterin have already entered the market, but they continue under formulation patents held by BioMarin.